Read by QxMD icon Read

decitabine hsct

X P Zong, L Tang, J N Cen, S N Chen, A N Sun, D P Wu
Objective: To investigate the characteristics of the essential thrombocythemia (ET) cases transformed to the acute myeloid leukemia (AML) and the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of this disease. Methods: The clinical and laboratory characteristics of 3 ET cases before and after transformation and after allo-HSCT were retrospectively analyzed, meanwhile the related literatures were reviewed and discussed. Results: Case 1 was a male patient of 44 years old, whose PLT was 500×10(9)/L when firstly diagnosed ET...
October 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Christian Flotho, Sebastian Sommer, Michael Lübbert
Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia. Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm occurring in young children. The common denominator of these malignant myeloid disorders is the limited benefit of conventional chemotherapy and a particular responsiveness to epigenetic therapy with the DNA-hypomethylating agents 5-azacytidine (azacitidine) or decitabine...
November 9, 2017: Seminars in Cancer Biology
Jie-Ke Cui, Yin Xiao, Yong You, Wei Shi, Qing Li, Yi Luo, Lin Jiang, Zhao-Dong Zhong
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a main question on treatment failure. Current strategies for management that usually include salvage chemotherapy, donor lymphocytic infusion and second transplantation. Our study assessed the efficacy of decitabine (DAC) for treating patients with acute lymphoblastic leukemia (ALL) who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed the outcomes of 12 patients with relapsed ALL after allo-HSCT who received DAC therapy...
October 2017: Journal of Huazhong University of Science and Technology. Medical Sciences
Carlo Finelli, Matilde Y Follo, Marta Stanzani, Sarah Parisi, Cristina Clissa, Sara Mongiorgi, Marilena Barraco, Lucio Cocco
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic diseases, mainly affecting the elderly, characterized by unilinear or multilinear peripheral cytopenia, bone marrow ineffective haemopoiesis, and a varying risk of progression to acute myeloid leukemia (AML). On the basis of the prognostic score systems currently used, MDS patients are generally classified as having higher risk (HR) or lower risk (LR) MDS. Two drugs, azacitidine (AZA) and decitabine (DAC), defined, because of their proven mechanism of action, as DNA methyltransferase inhibitors (DNMTIs), or hypomethylating agents (HMAs), have proven effective in improving peripheral cytopenias and quality of life, reducing or eliminating transfusion need, delaying leukemic evolution, and (only for AZA) prolonging overall survival (OS)...
2016: Current Pharmaceutical Design
Yi-Zhi Jiang, Gui-Ping Su, Yan Dai, He-Sheng He, Lai-Quan Huang, Zi-Min Sun, Dong-Ping Huang
Patients with relapsed or refractory acute myeloid leukemia (rAML) have a poor prognosis if they do not undergo hematopoietic stem cell transplantation (HSCT). We describe a case herein of acute myeloid leukemia (AML) with monosomy 7 and EVI1(+)(-7/EVI1(+)) in a patient who failed to achieve a complete remission (CR) after two cycles of standard induction chemotherapy. He subsequently received decitabine (DAC) as "bridge therapy" and directly underwent unrelated cord blood transplantation (UCBT) due to the absence of an available sibling donor...
2015: Annals of Clinical and Laboratory Science
Su Gao, Zheng Li, Jian-Hong Fu, Xiao-Hui Hu, Yang Xu, Zheng-Ming Jin, Xiao-Wen Tang, Yue Han, Su-Ning Chen, Ai-Ning Sun, De-Pei Wu, Hui-Ying Qiu
BACKGROUND: We conducted a study exploring the clinical safety and efficacy of decitabine in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), combined with a complex karyotype. MATERIALS AND METHODS: From April 2009 to September 2013, a total of 35 patients with AML/MDS combined with a complex karyotype diagnosed in the First Affiliated Hospital of Soochow University were included for retrospective analysis. All patients were treated with decitabine alone (20 mg/m2 daily for 5 days) or combination AAG chemotherapy (Acla 20 mg qod*4d, Ara-C 10 mg/m2 q12h*7d, G-CSF 300 μg qd, the dose of G-CSF adjusted to the amount in blood routinely)...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
Jing Yuan, Hanyun Ren, Zhixiang Qiu, Yuan Li, Mangju Wang, Wei Liu, Weilin Xu, Yuhua Sun, Lihong Wang, Zeyin Liang, Yujun Dong, Jinping Ou, Wensheng Wang, Yue Yin, Xinan Cen, Qian Wang
OBJECTIVE: To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (MDS-AML) using conditioning regimen with busulfan (Bu) and increased-dose of fludarabine (ID-Flu). METHODS: A total of 49 patients with MDS or MDS-AML were treated by allo-HSCT, the clinical data was analyzed retrospectively. RESULTS: All patients achieved hematopoietic reconstitution...
June 2015: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Daniel A Roberts, David P Steensma
The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 % of patients experience complete hematologic and cytogenetic response. Moreover, once an HMA fails the patient, the prognosis is poor, with a median survival of less than 6 months unless the patient undergoes hematopoietic stem cell transplantation (HSCT)...
September 2015: Current Hematologic Malignancy Reports
Jin Zhou, Jing Wang, Hui Liu, Huifei Zheng, Ling Ma, Panfeng Wang, Shuang Yan, Depei Wu, Chengcheng Fu, Huiying Qiu, Xiaowen Tang, Zhengming Jin, Yue Han, Miao Miao
OBJECTIVE: To explore the therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation (HSCY) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). METHODS: Retrospective reviews were conducted for 46 patients with MDS (n = 14) and AML (n = 32) on a therapy of decitabine prior to allo-HSCT between September 2009 and February 2013. RESULTS: In MDS patients, complete remission (CR, n = 10), partial remission (PR, n = 2) and stable disease (SD, n = 1) were achieved prior to HSCT...
March 31, 2015: Zhonghua Yi Xue za Zhi [Chinese medical journal]
C Zhang, X-H Chen, J Liu, L Gao, Y Liu, L Gao, P-Y Kong, X Zhang
WHAT IS KNOWN AND OBJECTIVE: Chemotherapy can increase treatment-related mortality associated with future haematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory acute myeloid leukaemia (AML). There is usually insufficient time to find a suitable unrelated donor for these patients. We report on the use of decitabine, a DNA methyltransferase inhibitor as a conditioning regimen for a patient undergoing HSCT. CASE SUMMARY: Our patient was a 21-year-old male diagnosed with AML-M1 with 84·5% blast cells and a normal karyotype...
June 2015: Journal of Clinical Pharmacy and Therapeutics
Huifei Zheng, Jing Wang, Jin Zhou, Panfeng Wang, Chengcheng Fu, Depei Wu, Aining Sun, Huiying Qiu, Zhengming Jin, Yue Han, Xiaowen Tang, Xiao Ma
OBJECTIVE: To evaluate the efficacy of decitabine (DAC) bridging therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic syndrome (MDS). METHODS: The clinical characteristics and curative effect of MDS patients who received allo-HSCT from 2010 July to 2013 December were retrospectively analyzed. Of them, 25 MDS patients who received decitabine bridging allo-HSCT were randomly selected (referred to as the bridging group),while at the same time another 33 MDS patients who did not receive decitabine for allo-HSCT in MDS were also randomly selected as control group...
February 2015: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Jing Wang, Jin Zhou, Hui-Fei Zheng, Zheng-Zheng Fu
Based on the representative articles in recent years, the different mechanisms of decitabine on immune regulation in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT) are summarized. Decitabine improves the expression of WT1 gene to stimulate specific cytotoxic T cells which can enhance graft versus leukemia effect (GVL) and improve the expression of FOXP3 gene to stimulate regulatory T cells so as to inhibit the acute graft versus host disease (GVHD)...
October 2014: Zhongguo Shi Yan Xue Ye Xue za Zhi
Changmei Hu, Liang Lv, Deliang Liu, Jirong Huo
Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract arising in individuals with genetic predisposing factors and abnormalities of the immune system. Myelodysplastic syndrome (MDS), an acquired clonal hematologic disorder, is characterized by peripheral blood cytopenia, dysplastic changes in several types of hematopoietic cells of the bone marrow and peripheral blood, and a high risk of transformation to acute leukemia. CD rarely occurs in combination with MDS, and MDS treatment with hematopoietic stem cell transplantation (HSCT) has not been frequently reported...
August 2014: Clinical Journal of Gastroenterology
Yue-Lu Guo, Min-Hang Zhou, Ting-Ting Cao, Li-Ping Dou, Xiao-Lin Lu, Qian-Fei Zhang, Zi-Long Yao, Li-Li Wang, Li Yu, Yu Jing
The aim of this study was to investigate the clinical characteristics and prognosis of acute erythroleukemia (AEL, AML-M6). The clinical features and results of morphologic, immunophenotypic, cytogenetic and molecular biologic detections were retrospectively analyzed in 13 cases of AEL from 305 acute leukemia patients hospitalized between October 2007 and October 2012. The results showed that the expression of erythroid and non-erythroid cells increased at the same time. The myeloid antigens mainly expressed CD13/CD33/CD117/CD34, while the erythroid antigens expressed Gly and CD71...
October 2013: Zhongguo Shi Yan Xue Ye Xue za Zhi
Lei Yuan, Lu Sun, Lin Yang, Yu Jing
BACKGROUND: With a well-developed strategy of acute graft-versus-host disease (aGVHD) prophylaxis, the prognosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients who develop aGVHD has improved considerably. Meanwhile, transfusion-associated GVHD (TA-GVHD) can be fatal. Recent advancements in immune cellular therapy are being adopted in clinical practice, although many concerns including TA-GVHD remain. This report describes a 64-year-old male non-HSCT candidate diagnosed with acute myeloid leukemia who had received decitabine followed by an infusion of granulocyte-colony-stimulating factor-primed peripheral blood stem cells (G-PBSCs) from his daughter, who carried haploidentical human leukocyte antigen...
January 2014: Transfusion
Mikkael A Sekeres, Nelli Bejanyan
Myelodysplastic syndromes (MDS) are clonal disorders of the hematopoietic system with resultant cytopenias and shortened survival. Better recognition of MDS and an aging population, some of whom have been treated with chemotherapy and radiation therapy for other cancers, is largely responsible for the growing incidence of this malignancy, which is divided into lower- and higher-risk subtypes. Erythropoiesis-stimulating agents are the first-line treatment options for patients with lower-risk MDS and symptomatic anemia or for those requiring transfusion support...
February 2011: Therapeutic Advances in Hematology
Roger M Lyons
Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic disorders characterized by dysplasia, peripheral cytopenias, and risk of progression to acute myeloid leukemia and death. In patients who are ineligible for potentially curative hematopoietic stem cell transplantation (HSCT), approved therapies such as lenalidomide, azacitidine, and decitabine are available for those who previously would have received supportive care alone. Each treatment can achieve hematologic improvement and enhance quality of life...
July 2012: American Journal of Medicine
Bei-Ming Shou, Bao-An Chen, De-Long Liu
DNA methylation is a frequent change in epigenetics of leukemia. In the development of leukemia, methylation plays an important role in the genetic expression regulation and genetic structure stabilization. Hematopoietic stem cell transplantation (HSCT) and chemotherapy are the common methods to cure leukemia at present. Unfortunately, it is very hard to find suitable donor for transplantation, while the relapse and drug resistance are the unresolved problems in chemotherapy. Because of the reversibility of methylation, the drugs reducing the level of methylation become a new way to cure leukemia...
October 2008: Zhongguo Shi Yan Xue Ye Xue za Zhi
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"